1242137-18-3

Basic information

• Product Name: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
• Synonyms: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
• CAS NO: 1242137-18-3
• Molecular Weight: 448.377
• Mol File: 1242137-18-3.mol
• Article Data: 3

Chemical Properties

• Density: 1.48±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(1242137-18-3)
• EPA Substance Registry System: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(1242137-18-3)

Safety Data

• Hazardous Substances Data: 1242137-18-3(Hazardous Substances Data)

Usage

Uses

Oxo-MDV 3100 (Oxo-enzalutamide) is an impurity of Enzalutamide (M199800), which is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. Enzalutamide has been shown to induce tumor cell apoptosis, and is used for the treatment of castration-resistant prostate cancer.

Upstream product

• 749927-69-3 4-bromo-2-fluoro-N-methylbenzanamide 
• 143782-20-1 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 101066-87-9 4-iodo-2-(trifluoromethyl)benzonitrile 
• 915087-33-1 enzalutamide 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Relevant articles and documents

Copper-Mediated N-Arylations of Hydantoins

A set of two broadly applicable procedures for the N-arylation of hydantoins is reported. The first one relies on the use of stoichiometric copper(I) oxide under ligand- A nd base-free conditions and enables a clean regioselective arylation at the N3 nitrogen atom, while the second one is based on the use of catalytic copper(I) iodide and trans-N,N′-dimethylcyclohexane-1,2-diamine and promotes arylation at the N1 nitrogen atom. Importantly, the combination of these two procedures affords a straightforward entry to diarylated hydantoins.

SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS

Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.